MAINRITSAN 3 – Rituximab maintenance therapy for ANCA vasculitis
The optimal duration of Rituximab maintenance therapy for ANCA vasculitis is not known. The French vasculitis group has just published an important article to help answer this question. In this MAINRITSAN-3 study (link), they randomised patients who had previously had 2 years of maintenance Rituximab and were in remission (disease was…
Read More